CA2646676A1 - Heterocyclic gpcr agonists - Google Patents

Heterocyclic gpcr agonists Download PDF

Info

Publication number
CA2646676A1
CA2646676A1 CA002646676A CA2646676A CA2646676A1 CA 2646676 A1 CA2646676 A1 CA 2646676A1 CA 002646676 A CA002646676 A CA 002646676A CA 2646676 A CA2646676 A CA 2646676A CA 2646676 A1 CA2646676 A1 CA 2646676A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
alkyl
compound according
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002646676A
Other languages
English (en)
French (fr)
Inventor
Lisa Sarah Bertram
Matthew Colin Thor Fyfe
Martin James Procter
Geoffrey Martyn Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0606913A external-priority patent/GB0606913D0/en
Priority claimed from GB0700112A external-priority patent/GB0700112D0/en
Application filed by Individual filed Critical Individual
Publication of CA2646676A1 publication Critical patent/CA2646676A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002646676A 2006-04-06 2007-04-05 Heterocyclic gpcr agonists Abandoned CA2646676A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0606913A GB0606913D0 (en) 2006-04-06 2006-04-06 Compounds
GB0606913.2 2006-04-06
GB0700112A GB0700112D0 (en) 2007-01-04 2007-01-04 Compounds
GB0700112.6 2007-01-04
PCT/GB2007/050183 WO2007116229A1 (en) 2006-04-06 2007-04-05 Heterocyclic gpcr agonists

Publications (1)

Publication Number Publication Date
CA2646676A1 true CA2646676A1 (en) 2007-10-18

Family

ID=38227799

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002646676A Abandoned CA2646676A1 (en) 2006-04-06 2007-04-05 Heterocyclic gpcr agonists

Country Status (12)

Country Link
US (1) US20090221639A1 (enExample)
EP (1) EP2013201B1 (enExample)
JP (1) JP2009532453A (enExample)
KR (1) KR20080109075A (enExample)
AU (1) AU2007235673A1 (enExample)
BR (1) BRPI0710839A2 (enExample)
CA (1) CA2646676A1 (enExample)
MX (1) MX2008012814A (enExample)
NO (1) NO20084307L (enExample)
NZ (1) NZ571869A (enExample)
WO (1) WO2007116229A1 (enExample)
ZA (1) ZA200809289B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700122D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
PE20081659A1 (es) * 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
WO2008081208A1 (en) * 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
GB0700125D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
EP2377863A1 (en) * 2007-01-04 2011-10-19 Prosidion Limited Piperidine GPCR agonists
CL2008000017A1 (es) * 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20100286112A1 (en) 2007-09-10 2010-11-11 Oscar Barba Compounds for the treatment of metabolic disorders
JP5465177B2 (ja) 2007-09-20 2014-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
WO2009117421A2 (en) * 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US20110065671A1 (en) * 2008-05-19 2011-03-17 Harris Joel M Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
ES2403120T3 (es) 2008-12-24 2013-05-14 Cadila Healthcare Limited Nuevos derivados de oxima
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201111361A (en) 2009-06-24 2011-04-01 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
TW201113269A (en) 2009-06-24 2011-04-16 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
BR112012002293A2 (pt) * 2009-08-05 2016-06-14 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, uso do composto
MY156174A (en) 2009-08-05 2016-01-15 Daiichi Sankyo Co Ltd 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
WO2011053688A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101563793B1 (ko) 2010-10-08 2015-10-27 카딜라 핼쓰캐어 리미티드 신규한 ｇｐｒ 119 작용물질
PL2628733T3 (pl) 2010-10-14 2015-05-29 Daiichi Sankyo Co Ltd Pochodna acylobenzenu
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US9181214B2 (en) 2011-06-09 2015-11-10 Rhizen Pharmaceuticals Sa Bicyclic compounds as modulators of GPR-119
MX2014000929A (es) 2011-07-29 2014-05-12 Daiichi Sankyo Co Ltd Derivados de amida sustituidos con n-hetero-anillo.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013062837A1 (en) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Piperidine derivatives useful as gpr119 agonists
CN104159892A (zh) 2012-01-18 2014-11-19 第一三共株式会社 被取代的苯基唑衍生物
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP2015523404A (ja) * 2012-08-02 2015-08-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032965A1 (en) * 1994-06-01 1995-12-07 Yamanouchi Pharmaceutical Co. Ltd. Oxadiazole derivative and medicinal composition thereof
US6699853B2 (en) * 1997-06-16 2004-03-02 Hoechst Schering Agrevo Gmbh 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides
IL149872A0 (en) * 1999-12-16 2002-11-10 Schering Corp Substituted imidazole neuropeptide y y5 receptor antagonists
TR201706226T4 (tr) * 2003-04-11 2018-06-21 Ptc Therapeutics Inc 1,2,4-oksadiazol benzoik asit bileşikleri ve bunların anlamsız baskılama ve hastalıkların tedavisinde kullanımı.
JP4958560B2 (ja) * 2003-12-24 2012-06-20 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
EP1907383A1 (en) * 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
KR20080025190A (ko) * 2005-06-30 2008-03-19 프로시디온 리미티드 Ｇ-단백질 결합된 수용체 효능제

Also Published As

Publication number Publication date
MX2008012814A (es) 2008-10-17
JP2009532453A (ja) 2009-09-10
WO2007116229A8 (en) 2007-12-27
BRPI0710839A2 (pt) 2011-08-23
KR20080109075A (ko) 2008-12-16
EP2013201B1 (en) 2012-07-25
WO2007116229A1 (en) 2007-10-18
ZA200809289B (en) 2012-06-27
NO20084307L (no) 2008-10-28
EP2013201A1 (en) 2009-01-14
US20090221639A1 (en) 2009-09-03
NZ571869A (en) 2011-11-25
AU2007235673A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
CA2646676A1 (en) Heterocyclic gpcr agonists
EP1838698B1 (en) Pyrimidine derivatives as gpcr agonists
JP4958560B2 (ja) Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
WO2007003960A1 (en) Gpcr agonists
US20110212939A1 (en) Heterocyclic GPCR Agonists
US20090221644A1 (en) Gpcr Agonists
AU2008203673A1 (en) Piperidine GPCR agonists
CA2674455A1 (en) Piperidine gpcr agonists
NZ556017A (en) G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
MX2007016545A (es) Agonistas del receptor acoplado a la proteina g.
US20120040953A1 (en) Compounds for the Treatment of Metabolic Disorders
CA2674355A1 (en) Piperidine gpcr agonists
JP2012520283A (ja) 代謝障害の治療のための化合物
WO2011128394A1 (en) 3-substituted 5-(pyrrolidine-1-carbonyl) pyrrolidine and its derivatives for use in the treatment of metabolic disorders
MXPA06007135A (en) Heterocyclic derivatives as gpcr receptor agonists
HK1135704B (en) Piperidine gpcr agonists

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140407